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Summary
    Matrix metalloproteinases and tissue inhibitor of metalloproteinases play an important role in the 
regulation of mesangial cell proliferation and may be involved in ischemia-reperfusion injuries. 
Preservation solutions are thought to diminish the ischemic injury and appropriate choice of the 
solution should guarantee a better graft function and good prognosis for graft survival. The aim 
of the study was to examine the effect of preservation solutions UW and EC on the expression 
of matrix metalloproteinase II and tissue inhibitor of metalloproteinase II genes in rat kidney.
    The study was carried out on Wistar rat kidneys divided into 3 groups: kidneys perfused with 
0.9% NaCl (control group), with UW, and with EC preservation solution.
    The results show an enhancement of MMP-2 and TIMP-2 gene expression after 12 min of cold 
ischemia. This increase was more expressed in kidneys preserved with UW solution in compa-
rison with kidneys perfused with EC solution and 0.9% NaCl. After 24 h of cold ischemia the 
expression of MMP-2 and TIMP-2 genes in kidney perfused with UW solution decreased, while 
in kidneys perfused with EC it was increased. After warm ischemia the MMP-2 and TIMP-2 gene 
expression increased, whereas it was significantly lower in kidneys perfused with EC solution.
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Streszczenie
    Metaloproteinazy macierzy oraz tkankowe inhibitory metaloproteinaz odgrywają istotną rolę 
w regulacji proliferacji komórek mezangium i mogą brać udział w procesie uszkodzenia niedo-
krwienno-reperfuzyjnego. Płyny konserwujące stosowane są w celu zmniejszenia uszkodzenia 
niedokrwiennego, ich właściwy wybór może wpływać na dalsze funkcjonowanie przeszczepu. 
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Matrix metalloproteinases (MMP) are a family of proteins 
that are capable of digesting extracellular matrix and ba-
sement membrane components under physiological con-
ditions. MMP are inhibited by tissue inhibitors of metal-
loproteinases (TIMP) through formation of non-covalent 
complexes with MMP [22]. The tissue inhibitor of metal-
loproteinases comprises a four-member family of homo-
logous MMP inhibitors [11]. The transcription of TIMP 
is regulated by similar cytokines and growth factors that 
control MMP expression. MMP and TIMP are involved in 
many biological processes, such as embryonic development, 
organ morphogenesis including the kidneys, and angioge-
nesis. Increased expression or activity of MMP was descri-
bed in cases of several different glomerular diseases, such 
as glomerulonephritis IgA nephropathy, and diabetic ne-
phropathy [24,27]. The precise role of MMP and TIMP in 
organ transplantation has not yet been clarified. However, 
chronic kidney allograft rejection is characterized by pro-
gressive fibrosis in which the regulation of extracellu-
lar matrix metabolism appears to be of high significance. 
Therefore, MMP and TIMP are likely candidates to play 
an active role in transplantation medicine [1,9].
MMP-2 plays an increasingly recognized role in the regu-
lation of mesangial cell proliferation in cell cultures and 
in glomerulonephritis. These proteolytic enzymes appe-
ar to induce the activation of glomerular mesangial cells 
[20]. Therefore, a continuous expression of mesangial cell 
MMP-2 as a result of inflammatory stimuli must finally 
contribute to the evolution of glomerulosclerosis. The di-
rect effect of MMP-2 on mesangial cell proliferation was 
confirmed in vivo, since infusion of activated MMP-2 into 
the renal artery demonstrated focal areas of mesangial cell 
proliferation in rat glomeruli [18]. Moreover, MMP play an 
important role in ischemia-reperfusion injury [25].
Recent studies show that MMP-2 is involved in seve-
ral acute biological processes independent of its ac-
tions on extracellular matrix proteins [16]. These inc-
lude platelet activation, regulation of vascular tone and 
Celem pracy była ocena wpływu płynów konserwujących UW i EC na ekspresję genów metalo-
proteinaz macierzy oraz tkankowych inhibitorów metaloproteinaz w nerce szczura.
    Badanie przeprowadzone na szczurach rasy Wistar podzielonych na 3 grupy: nerki perfundowa-
ne 0,9% NaCl (grupa kontrolna), grupa perfundowana płynem UW, grupa perfundowana płynem 
EC. Wyniki wykazały nasilenie ekspresji genu MMP-2 i TIMP-2 po 12 min zimnego niedokrwie-
nia. Wzrost ten był najbardziej nasilony w nerkach perfundowanych płynem EC w porównaniu 
z nerkami perfundowanymi płynem UW i 0,9% NaCl. Po 24 h zimnego niedokrwienia ekspresja 
genów MMP-2 i TIMP-2 w nerkach perfundowanych płynem UW zmalała, natomiast EC wzro-
sła. Po okresie ciepłego niedokrwienia ekspresja genów MMP-2 i TIMP-2 wzrosła, jednakże była 
istotnie mniejsza w nerkach perfundowanych płynem EC.
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Component Euro-Collins 
(EC) [mM]
University 
of Wisconsin 
(UW) [mM]
Sodium 10 35
Potassium 115 125
Magnesium 30 5
Sulphate 30 5
Phosphate 50 25
Chloride 15 –
Bicarbonate 10 100
Glucose 140 –
Raffinose – 30
Glutathione – 3
Adenosine – 5
Allopurinol – 1
Hydroxyethyl starch – 50 g/L
Dexamethasone – 16 mg/L
Insulin – 40 U/L
Penicillin – 2×105 U/L
Table 1. Composition of UW and EC storage solutions
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transplanted kidney. MMP-2 is activated during oxidati-
ve stress injury and is responsible for the degradation of 
cytoskeletal proteins.
Preservation solutions are thought to diminish the ische-
mic injury and appropriate choice of the solution sho-
uld guarantee a better graft function and good prognosis 
for graft survival. Many studies concerning the influen-
ce of preservation solutions on the obtained kidney have 
been published, but the assessment is still ambiguous [4]. 
University of Wisconsin (UW) and Euro-Collins (EC) so-
lutions are often compared. The components of both so-
lutions are presented in Table 1.
The aim of the study was to examine the effect of prese-
rvation solutions UW and EC on the expression of matrix 
metalloproteinase II and tissue inhibitor of metalloprote-
inase II genes in rat kidney.
MaterIal and Methods
Animals
The study was approved by the local ethics committee 
(No11/02/2002). Male Wistar rats weighing 300–350 g were 
used in this experiment. They were allowed to acclimatize 
for a minimum of 10 days prior to the study. The rats were 
housed in a room maintained at 21±1°C with a 12-h light-
-dark cycle with the light cycle beginning at 6:00 a.m. All 
animals were fed standard rat chow and water ad libitum. 
Food was withheld overnight before surgery.
The rats were divided into 3 groups as follows:
•	 	 group	NaCl,	in	which	kidneys	were	perfused	with	0.9%	
NaCl (control group) (n=8);
•	 	 group	UW,	in	which	kidneys	were	perfused	with	UW	
preservation solution (n=8);
•	 	 group	EC,	in	which	kidneys	were	perfused	with	EC	pre-
servation solution (n=8).
Experimental protocol
The rats were anesthetized with ketamine (Ketolar). The 
abdominal cavity was opened via middle incision. The aor-
ta, vena cava inferior, and finally left and right renal ves-
sels were atraumatically isolated. The catheter (Becton 
Dickinson Vascular Access Inc., Sandy, Utah USA) was 
inserted in the aorta. The aorta and vena cava superior were 
clamped over the right and left renal artery, and then the 
vena cava inferior was catheterized to enable the outflow 
of perfusion solution.
The solutions were perfused in the aorta continuously at 
100 ml/h for 12 minutes (temperature of the solution +4°C, 
volume of injected solution 20 ml). The perfusion was per-
formed using a perfusion pump (Duet Nowa Standard 50). 
Finally, bilateral nephrectomy was performed.
The left kidneys were divided into two equal parts. The 
upper parts of left kidneys were immediately frozen in 
liquid nitrogen (cold ischemia 0). The lower parts of left 
kidneys and right kidneys were placed in cold (0–4°C) 
UW, EC or 0.9% NaCl solution for 24 hours (cold ische-
mia 24 h).
The lower parts of left kidneys were frozen using liquid 
nitrogen. The organs were preserved at the temperature of 
–70°C until evaluation. Subsequently the right kidneys were 
incubated in 0.9% NaCl at temp 20°C for 30 min (warm 
ischemia). Then the kidneys were frozen using liquid ni-
trogen. The organs were preserved at the temperature of 
–70°C until evaluation.
The expression of studied genes was assessed using the 
RT-PCR method as previously described [3].
Statistical analysis
The parameters were statistically evaluated using ANOVA 
and Tukey test.
results
The expression of MMP-2 gene after 12 min of cold ische-
mia (cold ischemia 0) in kidneys perfused with UW and 
EC solutions was significantly increased in comparison 
with kidneys from the control group. Moreover, the MMP-
2 gene expression in kidneys perfused with UW solution 
was significantly higher in comparison with kidneys per-
fused with EC solution (Table 2). After 24 h of cold ische-
mia the MMP-2 gene expression in control kidneys did not 
differ from baseline values (cold ischemia 0), in kidneys 
perfused with EC solution it was increased in comparison 
with baseline values, whereas in kidneys perfused with 
UW solution it was decreased.
Period
Group (X±SD)
p
Control [cu] EC [cu] UW [cu]
ICI0  0.22±0.18  0.77±0.47  3.36±1.17*,# <0.001
CI24  0.30±0.23  1.63±0.71*  0.87±0.43# <0.001
WI  4.32±1.50  2.14±1.03*  4.08±0.65 <0.01
p <0.001 <0.001 <0.001 –
Table 2. MMP-2 gene expression in rat kidneys of the control, EC and UW solution groups
ICI0 – initial period of cold ischemia; CI24 – 24 h cold ischemia; WI – warm ischemia; * p<0.05 as compared with control group; # p<0.05 as compared 
with EC group; cu – conventional unit – multiplication of constant mRNA expression of ribosomal protein L19.
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were significantly increased in the control group, as well as 
in kidneys perfused with EC and UW solutions compared 
with baseline values (cold ischemia 0) and values after 24 
h of cold ischemia. Nevertheless, expression of the MMP-2 
gene in kidneys perfused with EC solution was significan-
tly decreased in comparison with kidneys from the control 
group and perfused with UW solution.
Expressions of the TIMP-2 gene after 12 min of cold ische-
mia (cold ischemia 0) in kidneys perfused with EC and UW 
solutions were significantly increased in comparison with 
kidneys from the control group. Moreover, the TIMP-2 gene 
expression in kidneys perfused with UW solution was si-
gnificantly higher in comparison with kidneys perfused 
with EC solution (Table 3). After 24 h of cold ischemia the 
TIMP-2 gene expression in control kidneys and perfused 
with EC solution did not differ from baseline values (cold 
ischemia 0), whereas in kidneys perfused with UW solu-
tion it was decreased in comparison with baseline values.
The TIMP-2 gene expression after warm ischemia time 
was significantly increased in the control group in com-
parison with baseline values (cold ischemia 0), and valu-
es after 24 h of cold ischemia, whereas in kidney perfused 
with EC and UW solution it did not differ from baseline 
values (Table 3).
dIscussIon
The preservation of the harvested organ constitutes a pre-
requisite for organ transplantation. For kidney preserva-
tion, hypothermia storage remains the most common tech-
nique in use. However, hypothermic organ preservation is 
associated with oxygen deprivation, which inevitably le-
ads to some degree of ischemia-reperfusion injury upon 
transplantation [19]. During the renal storage before trans-
plantation, hypothermic swelling of the medullary thick 
ascending tubules results in mechanical constriction of the 
peritubular capillaries and vasa recta [5]. During the reper-
fusion, a large amount of reactive oxygen agents (supero-
xide anions, hydroxyl radicals, and hydrogen peroxides) is 
produced by the re-entry of oxygenated blood in the ische-
mic tissue. Euro-Collins and University of Wisconsin solu-
tions are the mainstay of therapy for hypothermic storage 
protection [12,30]. Nevertheless, the delayed graft func-
tion related to acute tubular necrosis (ATN) still remains an 
important complication after transplantation [21]. Recent 
studies have demonstrated that ischemia and reperfusion 
contribute to the non-immunological damage that compli-
cates transplantation [17].
In our study we investigated the expressions of MMP-2 and 
TIMP-2 genes in rat kidneys perfused with UW and EC 
solutions. The cellular and molecular mechanisms under-
lying the changes during ischemia-reperfusion remain not 
fully understood. MMP are important regulators of matrix 
deposition, and uncontrolled matrix remodeling. Our stu-
dy showed increased expression of the MMP-2 gene after 
reperfusion in kidneys perfused with UW solution. After 
warm ischemia, expression of the MMP-2 gene was si-
gnificantly lower in kidneys perfused with EC solution in 
comparison with control kidneys and perfused with UW 
solution. The TIMP-2 gene expression was significantly 
increased in kidneys perfused with UW solution, whereas 
after warm ischemia there were no significant differences 
between studied groups.
MMP-2 and TIMP-2 play important roles in tubular fi-
brosis and extracellular matrix deposition. Lutz et al. [17] 
showed that early MMP inhibition resulted in significan-
tly reduced protein excretion that was paralleled by a lo-
wer grade of chronic allograft nephropathy. Rodrigo et al. 
showed that serum MMP-2 was significantly higher in pa-
tients with chronic transplant nephropathy than in patients 
with acute rejection, stable graft function and healthy do-
nors. In an experimental study in chronic renal allograft 
rejection, mRNAs of MMP-2, MMP-12 and TIMP-1 and 
TIMP-2 were found to be significantly augmented [26]. 
Nicholson et al. found that intragraft expression of mRNA 
for TIMP-1 and TIMP-2 is significantly correlated with hu-
man allograft fibrosis and expression of TGF-b [23]. These 
authors concluded that alterations in the ratio of TIMP and 
MMP in the transplant kidney may be an important mo-
lecular mechanism leading to the development of tubulo-
-interstitial fibrosis [28].
Renal ischemia-reperfusion injury is the major cause of acu-
te renal failure and may also be involved in the development 
and progression of some forms of chronic kidney disease.
Previous studies have shown that MMP play an impor-
tant role in ischemia-reperfusion injury and subsequent 
progression to chronic allograft nephropathy [15,25]. Up-
regulation of MMP propagates the inflammatory response 
that drives ischemia-reperfusion injury. On the other hand, 
Period
Group (X±SD)
p
Control [cu] EC [cu] UW [cu]
ICI0  0.32±0.18  1.78±0.67*  2.83±0.70*,# <0.001
CI24  0.33±0.14  2.16±0.99*  0.76±0.40# <0.001
WI  2.19±1.02  2.31±1.23  2.47±1.86 NS
p <0.001 NS <0.005 –
Table 3. TIMP-2 gene expression in rat kidneys of the control, EC and UW solution groups
ICI0 – initial period of cold ischemia; CI24 – 24 h cold ischemia; WI – warm ischemia; * p<0.05 as compared with control group; # p<0.05 as compared 
with EC group; NS – non-significant; cu – conventional unit – multiplication of constant mRNA expression of ribosomal protein L19.
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sion kidney injury and tubular fibrosis [10,14].
The above reports indicate the important role of MMP in 
ischemia-reperfusion injury, tubular fibrosis and develop-
ment of chronic allograft nephropathy.
Previous studies showed the increased expression of MMP-2 
and TIMP-2 during I/R.
The enzymatic activity of MMP-2 located on the cell sur-
face is specifically inhibited by TIMP-2 [29]. Hypoxia-
induced MMP-2 shows a dual effect, affecting both cell de-
ath and cell life. In the I/R model a significant increase was 
demonstrated both in MMP-2 activity and TIMP-2 protein 
levels by reoxygenation. The increase in MMP-2 secretion 
caused by reoxygenation may be stimulated by the oxidati-
ve stress which occurs following reoxygenation. Gashe et 
al. reported that the activation of MMP-2 increased with 
oxidative stress [7]. TIMP-2 protein level may be inter-
preted as a compensation mechanism related to increased 
proMMP-2. In contrast to the findings of previous studies 
reporting that MMP-2 protein is expressed by endothelial 
cells, it has been stated that MMP-2 transcription also in-
creases through hypoxia-induced AP-1 (activating prote-
in-1) and hypoxia-inducible factor-1-a [2,13]. However, 
these responses may be cell-specific and depend on the 
experimental model and conditions used. Both angioge-
nesis and cell death involve the degradation of basal mem-
brane and extracellular matrix, as well as the impairment 
of cell–cell and cell–matrix interactions. It is reported that 
high levels of MMP cause cells to become detached from 
the extracellular matrix, directing them toward apoptosis 
[6]. Reperfusion was also shown to result in structural and 
biochemical changes in endothelial cells, leading to dama-
ged endothelium [8]. In summary, our results show an en-
hancement of MMP-2 and TIMP-2 gene expression after 
12 min of cold ischemia. This increase was more expres-
sed in kidneys preserved with UW solution in comparison 
with kidneys perfused with EC solution and 0.9% NaCl. 
After 24 h of cold ischemia the expression of MMP-2 and 
TIMP-2 genes in kidney perfused with UW solution de-
creased, while in kidneys perfused with EC it was incre-
ased. After warm ischemia the MMP-2 and TIMP-2 gene 
expression increased, whereas it was significantly lower in 
kidneys perfused with EC solution.
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